TScan Therapeutics (NASDAQ:TCRX – Get Free Report) is one of 842 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its peers? We will compare TScan Therapeutics to similar businesses based on the strength of its valuation, profitability, analyst recommendations, risk, earnings, dividends and institutional ownership.
Analyst Ratings
This is a summary of current ratings and target prices for TScan Therapeutics and its peers, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| TScan Therapeutics | 1 | 3 | 2 | 0 | 2.17 |
| TScan Therapeutics Competitors | 9951 | 15359 | 45765 | 1602 | 2.54 |
TScan Therapeutics presently has a consensus target price of $2.67, indicating a potential upside of 1,727.74%. As a group, “Biotechnology” companies have a potential upside of 114.69%. Given TScan Therapeutics’ higher probable upside, analysts clearly believe TScan Therapeutics is more favorable than its peers.
Profitability
This table compares TScan Therapeutics and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| TScan Therapeutics | -2,219.19% | -140.75% | -61.90% |
| TScan Therapeutics Competitors | -12,224.75% | -204.85% | -31.52% |
Earnings and Valuation
This table compares TScan Therapeutics and its peers revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| TScan Therapeutics | $10.32 million | -$129.77 million | -0.17 |
| TScan Therapeutics Competitors | $688.58 million | $7.69 million | -17.98 |
TScan Therapeutics’ peers have higher revenue and earnings than TScan Therapeutics. TScan Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Institutional and Insider Ownership
82.8% of TScan Therapeutics shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 13.8% of TScan Therapeutics shares are owned by insiders. Comparatively, 13.2% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Volatility & Risk
TScan Therapeutics has a beta of 1.21, indicating that its share price is 21% more volatile than the S&P 500. Comparatively, TScan Therapeutics’ peers have a beta of -1.85, indicating that their average share price is 285% less volatile than the S&P 500.
Summary
TScan Therapeutics beats its peers on 7 of the 13 factors compared.
TScan Therapeutics Company Profile
TScan Therapeutics is a clinical-stage biotechnology company developing engineered T cell receptor (TCR) T cell therapies for cancer. Its approach is designed to equip a patient’s T cells to recognize and attack cancer cells bearing specific targets. The company’s research and development programs include therapies for blood cancers and solid tumors. TScan uses its technology platform to identify cancer-associated targets and develop TCRs directed at them, with the goal of creating treatments for patients whose cancers express those targets.
Receive News & Ratings for TScan Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TScan Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
